Biotechnology company Agenus announced yesterday it has received additional demand for its previously announced registered direct offering. On Sept. 19, the company accepted additional commitments from both new and existing institutional investors to purchase an added $3.5 million of common stock and warrants in the previously announced registered direct offering. Aggregate gross proceeds in the offering will be around $10 million.
As announced previously, the offering consists of units of common stocks and warrants, with each unit consisting of one share of common stock and a warrant to buy 0.3 of a share of common stock. Each unit will be sold for a purchase price of $3.00. Warrants to purchase additional shares will be exercisable at a price of $3.75 per share starting six months after issuance and will expire five years from the initial exercisable date of the warrants. It is anticipated that the offering’s closing will still take place on or around Sept. 23, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. LLC served as exclusive placement agent for the offering.
A shelf registration statement relating to the shares issued in this offering (File No. 333-185657) has been filed with and declared effective by the Securities and Exchange Commission. Agenus will file a prospectus supplement with the SEC relating to the offering. Copies of the prospectus supplement and accompanying prospectus can be accessed at www.sec.gov or received by request from H.C. Wainwright & Co., [email protected], or by mail from Agenus, Inc., 3 Forbes Rd., Lexington, Mass. 02421.
For more information about Agenus, visit www.agenusbio.com
Let us hear your thoughts below: